CD4 and myeloid sarcoma: Importantly, there is high concordance of the cis-mQTL effects in CD4+ T cells from MS patients (our study) with those found from healthy individuals (the BLUEPRINT and GOLDN studies), which (1) increases our confidence in the robustness of all resources and (2) suggests that the majority of our cis-mQTL effects are not specific to MS.